FindTrial
Sign In

Whole exome sequencing of patients having comorbidities associated with type 2 diabetes.

Identification of risk alleles associated with Diabetes Kidney Disease (DKD) using the whole exome sequencing approach - ZiDA

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2020/01/022821
Enrollment
20000
Registered
2020-01-16
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E112- Type 2 diabetes mellitus with kidney complications

Interventions

Control Intervention1: Nil: NIL, This is an observational study

Sponsors

Zifo RnD Solutions
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Case and control group will be confirmed based on Blood Fasting Glucose, Hb1AC, UACR, Serum Ceratinine and eGFR

Exclusion criteria

Exclusion criteria: No history of Type 1 diabetes No nephropathy unrelated to diabetic nephropathy

Design outcomes

Primary

MeasureTime frame
1) Identification of biomarkers to study disease progression / pathophysiology Timepoint: 3 to 4 years down the line.—

Secondary

MeasureTime frame
1) Person specific tailored effective, safe medicine and dose (pharmacogenomics) 2) Biomarker based early diagnosis (preventive medicine)Timepoint: 3 to 4 years down the line—

Countries

India

Contacts

Public ContactJawahar Jagamoorthy

Zifo RnD Solutions

ratnesh.m@zifornd.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026